Norway, Dec. 16 -- Lifecare ASA (LIFE), a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, today announces that the first implant from a new production batch has been successfully implanted, marking an important step in demonstrating manufacturing reproducibility and process control under the company's updated production protocol.The manufacturing milestone relates to the full implantable product, integrating Lifecare's proprietary sensing technology with electronics, wireless communication and encapsulation into a medical-grade device designed for implantation. While Lifecare has previously demonstrated the ability to produce individual sensor components, the ability to reproducibly man...